This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Health Winners & Losers

A few health stocks, including Biogen Idec (BIIB), gained ground Thursday on business and clinical updates on a flat-to-positive day for the sector.

Biogen climbed after it reaffirmed 2007 guidance and said it expects to grow revenue by 15% a year and earnings per share (before charges and expenses) by 20% a year from 2007 to 2010.

The company said it expects the growth to be driven by continued performance of multiple sclerosis treatment Avonex, expansion of cancer treatment rituxan into autoimmune diseases, achieving a milestone of 100,000 patients on Tysabri by the end of 2010, and geographic diversification of its revenue base -- aiming for 40% of revenue to be from international business by 2010. Shares gained $3.66, or 5.83%, to $66.53.

Cell Therapeutics (CTIC) said following a meeting with the Food and Drug Administration it will conduct a full analysis of a late-stage study for its non-Hodgkin's lymphoma candidate pixantrone instead of an interim analysis.

The company expects the study to be completed by the end of the year and said a full analysis should be available during the first half of 2008. Cell Therapeutics said that since pixantrone has fast-track status for this indication, it could receive marketing approval in 2009. Shares rose 19 cents or 5.1%, to $3.90.

Others rose on mid-to-late stage trial initiation updates.

Introgen Therapeutics (INGN) and Moffitt Cancer Center announced plans to begin a phase II randomized, controlled study of INGN 225, Introgen's investigational immunotherapy product in patients with metastatic small-cell lung cancer.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs